- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00975351
Estimation of Plasma Folate Apparent Volume of Distribution in Adults (FOLCAN)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Bioavailability is a major determinant of nutritional status. In order to determine a safe level of folate fortification, its bioavailability must be assessed, so that risk-benefit analysis can be carried out. Recently, a mathematical model of folate true absorption which takes into account the liver first pass was devised (ref 1). In this model, the volume of distribution is a convenient method for describing how well a nutrient is removed from plasma and distributed into tissues.
In this study, volume of distribution will be more accurately estimated using an intravenous dose of labelled (13C5) dose of natural folate (5-methyltetrahydrofolic acid) in healthy adults aged 18-65, over a wide body mass index (BMI) range.
Healthy adults will be given an IV dose of a small amount of 13C5 5-methyltetrahydrofolic acid, and blood samples will be taken at regular time points via a cannula over a 2hr time period.
The primary objective is to estimate the sampled plasma pool volume of distribution in order to quantify the fraction of any folate test dose, or folate metabolites, appearing in systemic plasma circulation in future studies of bioavailability.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Norfolk
-
Norwich, Norfolk, Det Forenede Kongerige, NR4 6JF
- Institute of Food Research
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Males and females
- Aged 18-65
- Body mass index above 19.5 and below 40
- Smokers and non-smokers
- Participation in the FolGene study
Exclusion Criteria:
- Pregnancy or been pregnant in last 12 months
- History of fits, seizures or blackouts
- Parallel participation in other research projects which invole dietary intervention and/or sampling of biological fluids/material which study nurses advice would affect either wellbeing of volunteer or the study data, apart from participation in the FolGene study
- Any person related to or living with a member of the study team
- Participation in another research project which involves blood sampling within the last 4 months unless total amount blood combined from both studies is less than 470ml
- Had donated blood within 16 weeks of starting the study
- Prescribed medication for epilepsy/seizures
- Diabetics
- History of any gastrointestinal disorder requiring medical treatment
- Any long term medical condition requiring active treatment which may affect volunteers wellbeing or the study data
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: IV dose of 5-methyltetrahydrofolic acid
IV test dose of 13C5-labelled 5-methyltetrahydrofolic acid to all eligible volunteers, followed by regular blood samplings over 2hr period taken via a cannula.
|
one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals.
Total 2hr "intervention".
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Estimation of sampled plasma pool volume of distribution for natural folates
Tidsramme: 2 hours
|
2 hours
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Paul Finglas, Quadram Institute Bioscience
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IFR4/2008
- 08/H0310/154
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med 13C5-labelled 5-methyltetrahydrofolic acid
-
Newcastle-upon-Tyne Hospitals NHS TrustUniversity of Nottingham; Quadram Institute BioscienceAfsluttetSund og raskDet Forenede Kongerige
-
University of Alabama at BirminghamAfsluttetAnalgesi | Akut smerteForenede Stater
-
M.D. Anderson Cancer CenterCelgene CorporationAfsluttetMyelodysplastisk syndrom | Akut myelogen leukæmiForenede Stater
-
LEO PharmaBayerAfsluttet
-
Kafrelsheikh UniversityUkendt
-
Roswell Park Cancer InstituteAfsluttetAkut myeloid leukæmi | Kronisk myelomonocytisk leukæmi | Myelodysplastisk syndrom | Alkyleringsmiddel-relateret akut myeloid leukæmi | Ildfast anæmi med overskydende eksplosioner i transformationForenede Stater
-
St. Louis UniversityRekrutteringSmertebehandling | ACL kirurgiForenede Stater
-
Roswell Park Cancer InstituteCelldex TherapeuticsAfsluttetAkut myeloid leukæmi | Kronisk myelomonocytisk leukæmi | Myelodysplastisk syndrom | Højrisiko Myelodysplastisk Syndrom | Refraktær anæmi | Sprænger 30 procent eller mindre af knoglemarvskerneholdige cellerForenede Stater
-
Henry Ford Health SystemAktiv, ikke rekrutterende
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityAfsluttetPrimær myelofibrose | Anæmi | Tilbagevendende Hodgkin-lymfom | Refraktært Hodgkin-lymfom | Anatomisk fase IV brystkræft AJCC v8 | Tilbagevendende akut myeloid leukæmi | Tilbagevendende myelodysplastisk syndrom | Refraktær akut myeloid leukæmi | Refraktær kronisk myelomonocytisk leukæmi | Refraktært myelodysplastisk... og andre forholdForenede Stater